ArticleCancer medicine2012

EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.

Roshan James et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.